Motohiro Nakajima1, Sharon Allen2, Mustafa al'Absi1. 1. Department of Family Medicine and Biobehavioral Health, University of Minnesota Medical School, Duluth, MN. 2. Department of Family Medicine and Community Health, University of Minnesota, Minneapolis, MN.
Abstract
INTRODUCTION: Evidence indicates that menstrual cycle phase plays a role in smoking withdrawal symptoms and craving. Stress increases these symptoms. Whether the stress regulatory mechanism is associated with menstrual phase and withdrawal symptoms is not well understood. METHODS: Thirty-seven female smokers and 16 female nonsmokers were asked to complete a laboratory session. In each group, approximately half of the participants were tested when they were in the follicular phase and the other half was tested in the luteal phase. The session included resting baseline, stress, and recovery periods. Saliva samples for the measurement of cortisol and subjective measures of craving and withdrawal symptoms were collected at the end of each period. RESULTS: A series of repeated measures analysis of covariance found a significant smoking group × menstrual phase × sampling time interaction in cortisol levels (p < .05). Follow-up analyses indicated a reduced cortisol stress response in the luteal group relative to the follicular group in smokers (p < .02). This difference was not found in nonsmokers. CONCLUSIONS: Menstrual cycle phase is related to hormonal stress response and smoking withdrawal symptomatology. IMPLICATIONS: We show influences of the menstrual cycle phase on stress response among smokers. This is demonstrated by a reduced cortisol response to stress in the luteal group relative to the follicular group among smokers. This menstrual phase difference was not found in nonsmokers.
INTRODUCTION: Evidence indicates that menstrual cycle phase plays a role in smoking withdrawal symptoms and craving. Stress increases these symptoms. Whether the stress regulatory mechanism is associated with menstrual phase and withdrawal symptoms is not well understood. METHODS: Thirty-seven female smokers and 16 female nonsmokers were asked to complete a laboratory session. In each group, approximately half of the participants were tested when they were in the follicular phase and the other half was tested in the luteal phase. The session included resting baseline, stress, and recovery periods. Saliva samples for the measurement of cortisol and subjective measures of craving and withdrawal symptoms were collected at the end of each period. RESULTS: A series of repeated measures analysis of covariance found a significant smoking group × menstrual phase × sampling time interaction in cortisol levels (p < .05). Follow-up analyses indicated a reduced cortisolstress response in the luteal group relative to the follicular group in smokers (p < .02). This difference was not found in nonsmokers. CONCLUSIONS: Menstrual cycle phase is related to hormonal stress response and smoking withdrawal symptomatology. IMPLICATIONS: We show influences of the menstrual cycle phase on stress response among smokers. This is demonstrated by a reduced cortisol response to stress in the luteal group relative to the follicular group among smokers. This menstrual phase difference was not found in nonsmokers.
Authors: Sherry A McKee; Rajita Sinha; Andrea H Weinberger; Mehmet Sofuoglu; Emily L R Harrison; Meaghan Lavery; Jesse Wanzer Journal: J Psychopharmacol Date: 2010-09-03 Impact factor: 4.153
Authors: Matthew J Carpenter; Himanshu P Upadhyaya; Steven D LaRowe; Michael E Saladin; Kathleen T Brady Journal: Nicotine Tob Res Date: 2006-10 Impact factor: 4.244
Authors: Adam M Leventhal; Andrew J Waters; Susan Boyd; Eric T Moolchan; Caryn Lerman; Wallace B Pickworth Journal: Exp Clin Psychopharmacol Date: 2007-02 Impact factor: 3.157
Authors: Andrea H Weinberger; Philip H Smith; Sharon S Allen; Kelly P Cosgrove; Michael E Saladin; Kevin M Gray; Carolyn M Mazure; Cora Lee Wetherington; Sherry A McKee Journal: Nicotine Tob Res Date: 2015-04 Impact factor: 4.244
Authors: Erin A McClure; Nathaniel L Baker; Kevin M Gray; Caitlyn O Hood; Rachel L Tomko; Matthew J Carpenter; Viswanathan R Ramakrishnan; Cole J Buchanan; Michael E Saladin Journal: Psychopharmacology (Berl) Date: 2019-12-03 Impact factor: 4.530
Authors: Rodolfo J Flores; Bryan Cruz; Kevin P Uribe; Victor L Correa; Montserrat C Arreguin; Luis M Carcoba; Ian A Mendez; Laura E O'Dell Journal: Psychoneuroendocrinology Date: 2020-05-05 Impact factor: 4.905
Authors: Mustafa al'Absi; Briana DeAngelis; Mark Fiecas; Alan Budney; Sharon Allen Journal: Psychopharmacology (Berl) Date: 2022-03-11 Impact factor: 4.415